News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
10+ emerging markets, Japan & ANZ transition in final phase
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
This acquisition marks Max Healthcare's entry into Lucknow
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
